Industries > Pharma > Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs

PUBLISHED: 19 July 2018
PAGES: 223
PRODUCT CODE: PHA0324
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0324 Categories: , Tags: , , , ,

The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 223-page report you will receive 83 tables and 71 figures– all unavailable elsewhere.

The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Top 25 Ophthalmic Drug Manufacturers 2018-2028

Report Scope

Global ophthalmic drugs market revenue forecasts from 2018-2028

• Global ophthalmic drugs market revenue orecasts from 2018-2028, by submarket:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

• Revenue forecasts from 2018-2028 of the leading ophthalmic drugs:
• Alphagan
• Avastin
• Azopt
• Eylea
• Lucentis
• Lumigan & Ganfort
• Other Ophthalmic Drugs
• Restasis
• Vigamix
• Xalatan/Xalacom

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Acucela
• Akorn
• Alimera Sciences
• Allergan
• Amakem
• Bayer
• Chengdu Kanghong
• EyeGate Pharmaceuticals
• Gene Signal
• Icon Biosciences
• MacuCLEAR
• Neurotech
• Novartis
• Omeros
• Ophthotech
• Otsuka Pharmaceutical
• Pfizer
• pSivida Corp.
• Regeneron
• Roche
• Santen
• Senju
• Shire
• ThromboGenics
• Valeant

• Our report provides an overview, revenue forecast from 2018-2028 of the ophthalmic drugs segment, revenue forecast from 2018-2028 of the leading drugs, product pipeline and SWOT Analysis, for these companies:
• Akorn
• Alcon
• Allergan
• Bausch & Lomb
• Bayer
• Novartis
• Pfizer
• Regeneron
• Roche
• Santen
• Senju
• Valeant

• Our report provides these Qualitative Analysis:
Drivers and Restraints of the Global Ophthalmic Drugs market
SWOT Analysis of selected leading companies
Porter’s Five Forces Analysis of the Global Ophthalmic Drugs Market

Visiongain’s study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category